Literature DB >> 8139285

Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome.

A Zipursky1, P Thorner, E De Harven, H Christensen, J Doyle.   

Abstract

In this report we describe the clinical and hematologic features of 23 cases of myelodysplasia (MDS) or acute megakaryoblastic leukemia (AMKL) occurring in Down's syndrome. MDS was characterized by thrombocytopenia, abnormal megakaryocytopoiesis, megakaryoblasts (< 30%) in the marrow and abnormal karyotype, the most common of which was trisomy 8, found in 7/15 patients with MDS. Three of five patients achieved a complete remission with low dose cytosine arabinoside, vincristine and retinyl palmitate. The high cure rate and the distinctive features of the leukemic process in these cases suggest that this type of MDS and AMKL are unique to patients with Down's syndrome.

Entities:  

Mesh:

Year:  1994        PMID: 8139285     DOI: 10.1016/0145-2126(94)90111-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  23 in total

1.  Hematopoietic disorders in Down syndrome.

Authors:  John K Choi
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 2.  Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.

Authors:  Kelly Faulk; Lia Gore; Todd Cooper
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

Review 3.  Prognosis and management of acute myeloid leukemia in patients with Down syndrome.

Authors:  J Timothy Caldwell; Yubin Ge; Jeffrey W Taub
Journal:  Expert Rev Hematol       Date:  2014-09-18       Impact factor: 2.929

4.  Down syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome.

Authors:  Yoann Vial; Julie Lachenaud; Alain Verloes; Marianne Besnard; Odile Fenneteau; Elodie Lainey; Alice Marceau-Renaut; Claude Preudhomme; André Baruchel; Hélène Cavé; Séverine Drunat
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941

Review 5.  Malignancy in children with trisomy 21.

Authors:  Karen R Rabin; James A Whitlock
Journal:  Oncologist       Date:  2009-01-28

Review 6.  Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.

Authors:  Ana C Xavier; Yubin Ge; Jeffrey W Taub
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568

7.  Lineage conversion from acute lymphoblastic leukemia to acute myeloid leukemia on rearrangement of the IgH gene in a patient with Down syndrome.

Authors:  Kazuya Tsuboi; Makoto Yazaki; Hiroshi Miwa; Shinsuke Iida; Shogo Banno; Atsushi Wakita; Masakazu Nitta; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

8.  The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.

Authors:  Y Ge; K M LaFiura; A A Dombkowski; Q Chen; S G Payton; S A Buck; S Salagrama; A E Diakiw; L H Matherly; J W Taub
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

9.  Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome.

Authors:  Diane C Cabelof; Hiral V Patel; Qing Chen; Holly van Remmen; Larry H Matherly; Yubin Ge; Jeffrey W Taub
Journal:  Blood       Date:  2009-07-24       Impact factor: 22.113

10.  RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.

Authors:  Holly Edwards; Chengzhi Xie; Katherine M LaFiura; Alan A Dombkowski; Steven A Buck; Julie L Boerner; Jeffrey W Taub; Larry H Matherly; Yubin Ge
Journal:  Blood       Date:  2009-07-28       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.